Institutional members access full text with Ovid®

Share this article on:

Risk Factors for Critical Disease and Death from Hand, Foot and Mouth Disease

He, Yilin MM*†; Yang, Jianguo BM*; Zeng, Guang MM; Shen, Tao MD; Fontaine, Robert E. MD; Zhang, Lijie MD; Shi, Guoqing MM; Wang, Yulin BM§; Li, Qin BM§; Long, Jiang MM§

Pediatric Infectious Disease Journal: September 2014 - Volume 33 - Issue 9 - p 966–970
doi: 10.1097/INF.0000000000000319
Pathogenesis and Host Response

Background: There has been a high mortality and morbidity rate of critical and fatal patients from hand, foot and mouth disease (HFMD) in China in recent. Causes for development of critical and fatal disease remain unclear.

Methods: We performed a case-control study to assess the association between use of drugs and development of critical disease and death from HFMD.

Results: We found that glucocorticoids treatment was associated with a greater incidence of severe HFMD, whereas andrographolides treatment was associated with a protective effect when they are used for treatment within 48 hours after onset or before being diagnosed as critical.

Conclusions: We recommend that glucocorticoids should not be used for mild HFMD and andrographolides should undergo clinical trials for treatment of enterovirus 71 infections.

From the *Taizhou Center for Disease Control and Prevention, Jiangsu Province, Taizhou; Chinese Field Epidemiology Training Program, Chinese Center for Disease Control and Prevention, Beijing, China; U.S. Centers for Disease Control and Prevention, Atlanta, GA; and §Chongqing Center for Disease Control and Prevention, Chongqing, China.

Accepted for publication February 9, 2014.

Y.H., J.Y. and G.Z. are first coauthors of this study.

This work was supported by Chinese Field Epidemiology Training Program, Chinese Center for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of Chinese Center for Disease Control and Prevention.

The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Yilin He, MM, Taizhou Center for Disease Control and Prevention, Jiangsu Province, China. E-mail: heyilin001@163.com

© 2014 by Lippincott Williams & Wilkins, Inc.